Literature DB >> 30390817

Hypoparathyroidism and the Kidney.

Munro Peacock1.   

Abstract

Hypocalcemia and hyperphosphatemia are the pathognomonic biochemical features of hypoparathyroidism, and result directly from lack of parathyroid hormone (PTH) action on the kidney. In the absence of PTH action, the renal mechanisms transporting calcium and phosphate reabsorption deregulate, resulting in hypocalcemia and hyperphosphatemia. Circulating calcium negatively regulates PTH secretion. Hypocalcemia causes neuromuscular disturbances ranging from epilepsy and tetany to mild paresthesia. Circulating phosphate concentration does not directly regulate PTH secretion. Hyperphosphatemia is subclinical, but chronically promotes ectopic mineralization disease. Vitamin D-thiazide treatment leads to ectopic mineralization and renal damage. PTH treatment has the potential for fewer side effects.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  1,25 dihydroxy vitamin D; Calcium homeostasis; Hypoparathyroidism; Kidney; PTH; Phosphate homeostasis; Tubular reabsorption calcium; Tubular reabsorption phosphate

Mesh:

Substances:

Year:  2018        PMID: 30390817     DOI: 10.1016/j.ecl.2018.07.009

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  5 in total

Review 1.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

Review 2.  Phosphate Metabolism in Health and Disease.

Authors:  Munro Peacock
Journal:  Calcif Tissue Int       Date:  2020-04-07       Impact factor: 4.333

3.  Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study.

Authors:  Elvira O Gosmanova; Kristina Chen; Lars Rejnmark; Fan Mu; Elyse Swallow; Allison Briggs; Olulade Ayodele; Nicole Sherry; Markus Ketteler
Journal:  Adv Ther       Date:  2021-03-09       Impact factor: 3.845

4.  Unrecognized Primary Hypoparathyroidism with Severe Hypocalcemia in the Presence of COVID-19 Infection.

Authors:  Domas Grigoravičius; Laura Šiaulienė; Žydrūnė Visockienė
Journal:  Acta Med Litu       Date:  2022-03-15

5.  Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.

Authors:  Giulia Puliani; Valeria Hasenmajer; Ilaria Simonelli; Valentina Sada; Riccardo Pofi; Marianna Minnetti; Alessia Cozzolino; Nicola Napoli; Patrizio Pasqualetti; Daniele Gianfrilli; Andrea M Isidori
Journal:  J Bone Miner Res       Date:  2022-05-20       Impact factor: 6.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.